Fsh receptor-binding inhibitor fragment(bi-10)
Modify Date: 2025-08-25 20:53:17
Fsh receptor-binding inhibitor fragment(bi-10) structure
|
Common Name | Fsh receptor-binding inhibitor fragment(bi-10) | ||
|---|---|---|---|---|
| CAS Number | 163973-98-6 | Molecular Weight | 1058.06 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 1757.1±65.0 °C at 760 mmHg | |
| Molecular Formula | C42H67N13O19 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 1016.4±34.3 °C | |
Use of Fsh receptor-binding inhibitor fragment(bi-10)FSH receptor-binding inhibitor fragment(bi-10) is a potent FSH antagonist. FSH receptor-binding inhibitor fragment(bi-10) blocks the binding of FSH to FSHR, and alteres FSH action at the receptor level. FSH receptor-binding inhibitor fragment(bi-10) results in the suppression of ovulation and causes follicular atresia of mice. FSH receptor-binding inhibitor fragment(bi-10) has the potential for utilizing to restrain the carcinogenesis of ovarian cancer by down-regulating overexpression of FSHR and ERβ in the ovaries[1]. |
| Name | L-Threonyl-L-α-glutamyl-L-asparaginyl-L-leucyl-L-α-glutamyl-L-prolyl-L-asparaginylglycyl-L-α-glutamylglycinamide |
|---|---|
| Synonym | More Synonyms |
| Description | FSH receptor-binding inhibitor fragment(bi-10) is a potent FSH antagonist. FSH receptor-binding inhibitor fragment(bi-10) blocks the binding of FSH to FSHR, and alteres FSH action at the receptor level. FSH receptor-binding inhibitor fragment(bi-10) results in the suppression of ovulation and causes follicular atresia of mice. FSH receptor-binding inhibitor fragment(bi-10) has the potential for utilizing to restrain the carcinogenesis of ovarian cancer by down-regulating overexpression of FSHR and ERβ in the ovaries[1]. |
|---|---|
| Related Catalog | |
| In Vivo | FSH receptor-binding inhibitor fragment(bi-10) (10, 20, 30, 40 mg/kg; 肌肉注射; 每天1次; 连续5天) 在大剂量 (30 mg/kg-40 mg/kg) 可抑制卵巢和卵泡发育，降低卵巢中 ERβ 和 FSHR mRNA 和蛋白质的表达水平，抑制 E2 的产生[1]。 Animal Model: Prepuberty Kunming female mice of 21-days old and body weight of 22.3±1.52g[1] Dosage: 10, 20, 30, 40 mg/kg Administration: Intramuscularly injection; once a day for five consecutive days Result: Could attenuate FSH promoting effect on the follicular development, resulting in the poor maturation of ovarian follicles. High dose (40mg/kg) treatment blocked the follicle development of mice. High dose of FRBI (40mg/kg) treatment blocked the follicle development of mice. |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 1757.1±65.0 °C at 760 mmHg |
| Molecular Formula | C42H67N13O19 |
| Molecular Weight | 1058.06 |
| Flash Point | 1016.4±34.3 °C |
| Exact Mass | 1057.467651 |
| LogP | -5.91 |
| Vapour Pressure | 0.0±0.6 mmHg at 25°C |
| Index of Refraction | 1.578 |
| Glycinamide, L-threonyl-L-α-glutamyl-L-asparaginyl-L-leucyl-L-α-glutamyl-L-prolyl-L-asparaginylglycyl-L-α-glutamyl- |
| L-Threonyl-L-α-glutamyl-L-asparaginyl-L-leucyl-L-α-glutamyl-L-prolyl-L-asparaginylglycyl-L-α-glutamylglycinamide |